Clinical Trials Recent clinical trial studies curcumin as an adjuvant therapy for the treatment of COVID-19
Recent clinical trial studies curcumin as an adjuvant therapy for the treatment of COVID-19.
Background
Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, anti-thrombotic, and anti-proliferative effects, which make it a promising candidate for the …
